Tags

Type your tag names separated by a space and hit enter

Clinical and institutional aspects of antidote therapy in Russia.
Przegl Lek. 2001; 58(4):290-2.PL

Abstract

The problem of antidote application for treatment of acute poisoning is related to epidemiology and characterization of poisoning cases, and possibilities for supplying antidotes to health care institutions. To investigate the situation in Russia we have analyzed reports by poisoning treatment centers for 1997-1999, comparison of medical aid standards for poisoning treatment in Russia with WHO recommendations. Acute poisoning pattern varies in different regions. Particularly, poisoning pattern in large cities in European Russia and the Urals is dominated by pharmaceuticals (up to 63.1%). Pesticide and insecticide poisoning cases do not exceed 1 to 2%, metal compounds and methemoglobin forming poisons (below 1% in each group). Antidotes are used in Russia in line with the recommendations adopted in international toxicological practice. The most actual are antagonists of opiates and benzodiazepines, physostigmine, atropine, pyridoxine, antagonists of beta-adrenergic blockers, activated charcoal. Such antidotes as DMPS (Unithiol), N-acetylcysteine, methylene blue, amyl nitrite (or sodium nitrite), complex formers of EDTA group are also included in the list of specific agents. The main problem is that some important antidotes are currently not produced in Russia. The Ministry of Health of the Russian Federation is taking efforts to launch production of some previously known and also newly developed important antidotes.

Authors+Show Affiliations

Toxicology Information and Advisory Center, Ministry of Health of the Russian Federation, 3 block 7, Sukharevskaya ploshad, 129090 Moscow, Russia. rtiac@mednet.ruNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

11450355

Citation

Ostapenko, Y N., et al. "Clinical and Institutional Aspects of Antidote Therapy in Russia." Przeglad Lekarski, vol. 58, no. 4, 2001, pp. 290-2.
Ostapenko YN, Luzhnikov EA, Nechiporenko SP, et al. Clinical and institutional aspects of antidote therapy in Russia. Przegl Lek. 2001;58(4):290-2.
Ostapenko, Y. N., Luzhnikov, E. A., Nechiporenko, S. P., & Petrov, A. N. (2001). Clinical and institutional aspects of antidote therapy in Russia. Przeglad Lekarski, 58(4), 290-2.
Ostapenko YN, et al. Clinical and Institutional Aspects of Antidote Therapy in Russia. Przegl Lek. 2001;58(4):290-2. PubMed PMID: 11450355.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical and institutional aspects of antidote therapy in Russia. AU - Ostapenko,Y N, AU - Luzhnikov,E A, AU - Nechiporenko,S P, AU - Petrov,A N, PY - 2001/7/14/pubmed PY - 2001/8/10/medline PY - 2001/7/14/entrez SP - 290 EP - 2 JF - Przeglad lekarski JO - Przegl Lek VL - 58 IS - 4 N2 - The problem of antidote application for treatment of acute poisoning is related to epidemiology and characterization of poisoning cases, and possibilities for supplying antidotes to health care institutions. To investigate the situation in Russia we have analyzed reports by poisoning treatment centers for 1997-1999, comparison of medical aid standards for poisoning treatment in Russia with WHO recommendations. Acute poisoning pattern varies in different regions. Particularly, poisoning pattern in large cities in European Russia and the Urals is dominated by pharmaceuticals (up to 63.1%). Pesticide and insecticide poisoning cases do not exceed 1 to 2%, metal compounds and methemoglobin forming poisons (below 1% in each group). Antidotes are used in Russia in line with the recommendations adopted in international toxicological practice. The most actual are antagonists of opiates and benzodiazepines, physostigmine, atropine, pyridoxine, antagonists of beta-adrenergic blockers, activated charcoal. Such antidotes as DMPS (Unithiol), N-acetylcysteine, methylene blue, amyl nitrite (or sodium nitrite), complex formers of EDTA group are also included in the list of specific agents. The main problem is that some important antidotes are currently not produced in Russia. The Ministry of Health of the Russian Federation is taking efforts to launch production of some previously known and also newly developed important antidotes. SN - 0033-2240 UR - https://wwww.unboundmedicine.com/medline/citation/11450355/Clinical_and_institutional_aspects_of_antidote_therapy_in_Russia_ L2 - https://medlineplus.gov/poisoning.html DB - PRIME DP - Unbound Medicine ER -